- Oops!Something went wrong.Please try again later.
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has GW Pharmaceuticals (GWPH) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
GW Pharmaceuticals is a member of our Medical group, which includes 844 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. GWPH is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for GWPH's full-year earnings has moved 16.32% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, GWPH has moved about 87.66% on a year-to-date basis. At the same time, Medical stocks have gained an average of 3.77%. As we can see, GW Pharmaceuticals is performing better than its sector in the calendar year.
Looking more specifically, GWPH belongs to the Medical - Products industry, which includes 77 individual stocks and currently sits at #155 in the Zacks Industry Rank. On average, this group has gained an average of 9.80% so far this year, meaning that GWPH is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track GWPH. The stock will be looking to continue its solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GW Pharmaceuticals PLC (GWPH) : Free Stock Analysis Report
To read this article on Zacks.com click here.